Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology.

@article{Ballow2012ImmuneRM,
  title={Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma \& Immunology and the European Academy of Allergy and Clinical Immunology.},
  author={Mark C. Ballow and Cezmi A. Akdis and Thomas B. Casale and Andrew J Wardlaw and Sally E. Wenzel and Zuhair K Ballas and Jan L{\"o}tvall},
  journal={The Journal of allergy and clinical immunology},
  year={2012},
  volume={130 2},
  pages={
          311-24
        }
}

Figures and Tables from this paper

Current Issues on Immunotherapy in Children
TLDR
In order to improve the clinical efficacy of SLIT, the authors are looking for new routes of administration, new allergens, new protocols as well as combination ofSLIT with other immune modulatory treatments.
Chapter 6 Current Issues on Immunotherapy in Children
TLDR
This chapter aims to give insight into the latest data on immunotherapy in treating children with allergic diseases, and looks for new routes of administration, new allergens, new protocols as well as combination of SLIT with other immune modulatory treatments.
Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry
TLDR
The clinical benefit of sensitization for patients with SAA receiving omalizumab may be particularly dependent on sensitization pattern, as polysensitized patients showed a higher tendency to be responders (GETE), but a lower tendency to improve the ACT result and reduce ER than non-polysENSitized patients.
Treatment approaches for the patient with T2 low asthma.
  • T. Carr
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2021
Endotype-Driven Approach for Chronic Rhinosinusitis
  • C. Bachert, P. Tomassen
  • Medicine, Biology
    Implementing Precision Medicine in Best Practices of Chronic Airway Diseases
  • 2019
Respiratory Allergies: A General Overview of Remedies, Delivery Systems, and the Need to Progress
TLDR
This review provides a brief, general description of current therapeutic resources and the state of research with regard to both drugs and medical devices in order to highlight their limits and the urgent need for progress.
Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis.
  • C. Bachert, C. Akdis
  • Biology, Medicine
    The journal of allergy and clinical immunology. In practice
  • 2016
Advances in pediatric asthma in 2012: moving toward asthma prevention.
  • S. Szefler
  • Medicine
    The Journal of allergy and clinical immunology
  • 2013
...
...

References

SHOWING 1-10 OF 152 REFERENCES
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.
TLDR
These promising data suggest that IL-4R is safe and effective in the treatment of moderate persistent asthma.
Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.
TLDR
A single dose of IL-4R appears safe and effective in moderate asthma, and the 1,500 microg dose appears as safe but significantly more effective than the 500microg dose.
Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma.
TLDR
Intranasal R-848 administration is an effective treatment for allergic airway disease and hijacks an otherwise proinflammatory immune process triggered by TLR7 to mediate long-lasting disease suppression.
Peroxisome Proliferator–activated Receptors α and γ Down-regulate Allergic Inflammation and Eosinophil Activation
TLDR
PPARs, PPAR-α and -γ are expressed in eosinophils and their activation inhibits in vitro chemotaxis and antibody-dependent cellular cytotoxicity, and might be of therapeutic interest for the regulation of allergic or inflammatory reactions by targeting both regulatory and effector cells involved in the immune response.
Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma.
TLDR
IL-13 has a role in allergen-induced airway responses in humans and further study is required to determine whether anti- IL-13 monoclonal antibodies will be beneficial clinically.
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
TLDR
This Review focuses on the emerging roles that DP1 and CRTH2 have in acute and chronic aspects of allergic diseases and proposes that, rather than having opposing actions, these receptors have complementary roles in the initiation and maintenance of the allergy state.
Treatment with the TLR7 agonist R848 induces regulatory T‐cell‐mediated suppression of established asthma symptoms
TLDR
This work addressed the question whether the TLR7 ligand resiquimod (R848), which has been shown to be protective in several experimental allergic asthma protocols, can also suppress typical asthma symptoms once the disease is established and found that the treatment attenuated allergic symptoms through a mechanism that required Tregs.
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.
TLDR
In this pilot study, a 6-week regimen of the AIC vaccine appeared to offer long-term clinical efficacy in the treatment of ragweed allergic rhinitis.
...
...